DMHCA

Item no.	HY-129098-10mg
Manufacturer	MedChem Express
CASRN	79066-03-8
Amount	10 mg
Quantity options	10mM/1mL 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	99.80
Formula	C26H43NO2
Citations	[1]Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5(13):e137230.
Smiles	C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N(C)C)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	79066-03-8
Available
Product Description	DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Metabolism-sugar/lipid metabolism
MolecularWeight	401.63
Clinical Information	No Development Reported
Manufacturers Research Area	Metabolic Disease
Solubility	DMSO : 7.69 mg/mL (ultrasonic)
Target	LXR
Manufacturers Target	LXR
Manufacturers Pathway	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mg

available

Request delivery time